Weijing Sun1,2, Anuj Patel3, Daniel Normolle4, Krishna Patel5, James Ohr6, James J Lee6, Nathan Bahary6, Edward Chu6, Natalie Streeter2, Summer Drummond7. 1. University of Kansas School of Medicine, Westwood, Kansas. 2. University of Kansas Cancer Center, Westwood, Kansas. 3. Division of Hematology-Oncology, Department of Medicine, Harvard University and Dana-Farber Cancer Institute, Boston, Massachusetts. 4. Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania. 5. Texas Oncology, Round Rock, Texas. 6. University of Pittsburgh School of Medicine and Hillman Cancer Center at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. 7. National Institute for Occupational Safety and Health (NIOSH) Research Branch, Centers for Disease Control and Prevention, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second-line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy. METHODS: In this single arm-study, patients with advanced/unresectable or metastatic biliary tract cancer who failed at least 1 line of systemic chemotherapy received regorafenib once daily on a schedule of 21-days on/7-days off in a 28-day cycle. Patients initially received a standard 160 mg dose. After toxicity assessments in the first 3 patients, the dose was reduced to 120 mg for subsequent patients, as preplanned. The primary endpoint was progression-free survival (PFS). Secondary objectives included overall survival (OS), the objective response rate, and the disease control rate. RESULTS: Forty-three patients received at least 1 dose of regorafenib, and 34 patients who received at least 1 cycle of treatment were evaluable for tumor response. The median PFS was 15.6 weeks (90% confidence interval, 12.9-24.7 weeks), and the median OS was 31.8 weeks (90% confidence interval, 13.3-74.3 weeks), with survival rates 40% at 12 months and 32% at 18 months. A partial response was achieved in 5 patients (11%), and 19 had stable disease (44%), for a disease control rate of 56%. The toxicity profile was as expected, with grade 3 and 4 adverse events reported in 40% of patients. The most common toxicities were hypophosphatemia (40%), hyperbilirubinemia (26%), hypertension (23%), and hand-foot skin reaction (7%). CONCLUSIONS: The current results suggest promising efficacy of regorafenib in patients with chemotherapy-refractory, advanced/metastatic biliary tract cancer, warranting further studies to confirm its clinical efficacy. There is a clear unmet need for effective therapies in patients who have advanced and metastatic biliary tract cancer.
BACKGROUND:Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second-line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy. METHODS: In this single arm-study, patients with advanced/unresectable or metastatic biliary tract cancer who failed at least 1 line of systemic chemotherapy received regorafenib once daily on a schedule of 21-days on/7-days off in a 28-day cycle. Patients initially received a standard 160 mg dose. After toxicity assessments in the first 3 patients, the dose was reduced to 120 mg for subsequent patients, as preplanned. The primary endpoint was progression-free survival (PFS). Secondary objectives included overall survival (OS), the objective response rate, and the disease control rate. RESULTS: Forty-three patients received at least 1 dose of regorafenib, and 34 patients who received at least 1 cycle of treatment were evaluable for tumor response. The median PFS was 15.6 weeks (90% confidence interval, 12.9-24.7 weeks), and the median OS was 31.8 weeks (90% confidence interval, 13.3-74.3 weeks), with survival rates 40% at 12 months and 32% at 18 months. A partial response was achieved in 5 patients (11%), and 19 had stable disease (44%), for a disease control rate of 56%. The toxicity profile was as expected, with grade 3 and 4 adverse events reported in 40% of patients. The most common toxicities were hypophosphatemia (40%), hyperbilirubinemia (26%), hypertension (23%), and hand-foot skin reaction (7%). CONCLUSIONS: The current results suggest promising efficacy of regorafenib in patients with chemotherapy-refractory, advanced/metastatic biliary tract cancer, warranting further studies to confirm its clinical efficacy. There is a clear unmet need for effective therapies in patients who have advanced and metastatic biliary tract cancer.
Authors: Sam J Lubner; Michelle R Mahoney; Jill L Kolesar; Noelle K Loconte; George P Kim; Henry C Pitot; Philip A Philip; Joel Picus; Wei-Peng Yong; Lisa Horvath; Guy Van Hazel; Charles E Erlichman; Kyle D Holen Journal: J Clin Oncol Date: 2010-06-07 Impact factor: 44.544
Authors: Anthony B El-Khoueiry; Cathryn J Rankin; Edgar Ben-Josef; Heinz-Josef Lenz; Philip J Gold; R Darryl Hamilton; Rangaswamy Govindarajan; Cathy Eng; Charles D Blanke Journal: Invest New Drugs Date: 2011-07-12 Impact factor: 3.850
Authors: A B El-Khoueiry; C Rankin; A B Siegel; S Iqbal; I-Y Gong; K C Micetich; O R Kayaleh; H-J Lenz; C D Blanke Journal: Br J Cancer Date: 2014-01-14 Impact factor: 7.640
Authors: D Yoshikawa; H Ojima; M Iwasaki; N Hiraoka; T Kosuge; S Kasai; S Hirohashi; T Shibata Journal: Br J Cancer Date: 2007-12-18 Impact factor: 7.640
Authors: Richard D Kim; Hanna K Sanoff; Andrew S Poklepovic; Heloisa Soares; Jongphil Kim; Jing Lyu; Yingmiao Liu; Andrew B Nixon; Dae Won Kim Journal: Cancer Date: 2020-05-26 Impact factor: 6.860
Authors: Maeve A Lowery; Howard A Burris; Filip Janku; Rachna T Shroff; James M Cleary; Nilofer S Azad; Lipika Goyal; Elizabeth A Maher; Lia Gore; Antoine Hollebecque; Muralidhar Beeram; Jonathan C Trent; Liewen Jiang; Bin Fan; Elia Aguado-Fraile; Sung Choe; Bin Wu; Camelia Gliser; Samuel V Agresta; Shuchi S Pandya; Andrew X Zhu; Ghassan K Abou-Alfa Journal: Lancet Gastroenterol Hepatol Date: 2019-07-09
Authors: Avani Athauda; Caroline Fong; David K Lau; Milind Javle; Ghassan K Abou-Alfa; Chigusa Morizane; Keith Steward; Ian Chau Journal: Cancer Treat Rev Date: 2020-03-12 Impact factor: 12.111
Authors: Gerald W Prager; Matthias Unseld; Fredrik Waneck; Robert Mader; Fritz Wrba; Markus Raderer; Thorsten Fuereder; Phillip Staber; Ulrich Jäger; Markus Kieler; Daniela Bianconi; Mir Alireza Hoda; Lukas Baumann; Alexander Reinthaller; Walter Berger; Christoph Grimm; Heinz Kölbl; Maria Sibilia; Leonhard Müllauer; Christoph Zielinski Journal: Oncotarget Date: 2019-01-29
Authors: Sara Massironi; Lorenzo Pilla; Alessandra Elvevi; Raffaella Longarini; Roberta Elisa Rossi; Paolo Bidoli; Pietro Invernizzi Journal: Cells Date: 2020-03-11 Impact factor: 6.600